title: Lower urinary tract symptom: still too much focus on the prostate?
abstract: OBJECTIVE
  Male patients with lower urinary tract symptoms have historically been managed in a prostate centric fashion. Population studies highlighting the prevalence and significance of storage symptoms, including nocturia, have meant a shift in the way men with lower urinary tract symptoms are assessed and managed. We review the recent guidelines and publications that have addressed this change in approach.
  
  
  RESULTS
  A new β-3 adrenoreceptor agonist has demonstrated significant improvement in storage symptoms and appears to be well tolerated.
  
  
  CONCLUSIONS
  We support a continued move towards a patient-focused and management using the current guidelines.
authors.affiliation: Bristol Urological Institute, Southmead Hospital, Bristol, UK.
authors.forename: Katherine
authors.initials: K
authors.lastname: Warren
authors.forename: Helena
authors.initials: H
authors.lastname: Burden
authors.forename: Paul
authors.initials: P
authors.lastname: Abrams
mesh_terms: D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D019983:Guideline Adherence; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D053158:Nocturia / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011467:Prostate / Q000187:drug effects* / Q000503:physiopathology; D009626:Terminology as Topic; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D058667:Adrenergic beta-3 Receptor Agonists